admin – Page 8274 – Get News Story

Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 | Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.

DelveInsight’s, “Triple Negative Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Triple Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Triple Negative Breast Cancer Pipeline Report

DelveInsight’s Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies.
The leading Triple Negative Breast Cancer Companies working in the market include Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
November 2023: Shanghai Jiaolian Drug Research and Development Co., Ltd announced a study of Phase 2 & 3 clinical trials for B013+Nab-Paclitaxel. This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
November 2023: Gilead Sciences announced a study of Phase 3 clinical trials for Pembrolizumab. The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician’s choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
November 2023: AstraZeneca announced a study of Phase 1 & 2 clinical trials for Datopotamab Deruxtecan (Dato-DXd). This is a Phase 1/Phase 2, multicentre, open-label, multiple-cohort study, which is designed to evaluate the efficacy, safety, Pharmacokinetic, and immunogenicity of Dato-DXd in adult Chinese participants with advanced or metastatic solid tumours. It is a single-arm study with no blinding.
On June 2023, Shanghai Jiaolian Drug Research and Development Co., Ltd announced a study of phase 2 & 3 clinical trials for B013+Nab-Paclitaxel. This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
On February 2023, Jina Pharmaceuticals announced a study of phase 3 clinical trials for Taxotere® (100 mg/m2). The trial will be conducted as per the ICH GCP Guidelines E6 (R1), Schedule Y (Amended Version 2013), Declaration of Helsinki (Fortaleza, Brazil, October 2013), ICMR Guidelines for Biomedical Research on Human subjects and in accordance with other applicable guidelines.

Request a sample and discover the recent advances in Triple Negative Breast Cancer Treatment Drugs @ Triple Negative Breast Cancer Infection Pipeline Report

In the Triple Negative Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Triple Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Triple Negative Breast Cancer Overview

Triple Negative Breast Cancer (TNBC) is defined as a tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.

Find out more about Triple Negative Breast Cancer Treatment Landscape @ Drugs for Triple Negative Breast Cancer Treatment

Triple Negative Breast Cancer Emerging Drugs Profile

Camrelizumab: Jiangsu HengRui Medicine
IPI-549: Infinity Pharmaceuticals
PMD-026: Phoenix Molecular Designs

Triple Negative Breast Cancer Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the therapies for Triple Negative Breast Cancer. The Triple Negative Breast Cancer companies which have their Triple Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine.

DelveInsight’s Triple Negative Breast Cancer pipeline report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
intravenous
Subcutaneous
Topical.

Triple Negative Breast Cancer Pipeline Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Learn more about the emerging Triple Negative Breast Cancer Pipeline Therapies @ Triple Negative Breast Cancer Clinical Trials Assessment

Scope of the Triple Negative Breast Cancer Pipeline Report

Coverage- Global
Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.

Dive deep into rich insights for new drugs for Triple Negative Breast Cancer treatment, Visit @ Triple Negative Breast Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Triple Negative Breast Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Camrelizumab: Jiangsu HengRui Medicine
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
IPI-549: Infinity Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
PMD-026: Phoenix Molecular Designs
Drug profiles in the detailed report…..
Inactive Products
Triple Negative Breast Cancer Key Companies
Triple Negative Breast Cancer Key Products
Triple Negative Breast Cancer- Unmet Needs
Triple Negative Breast Cancer- Market Drivers and Barriers
Triple Negative Breast Cancer- Future Perspectives and Conclusion
Triple Negative Breast Cancer Analyst Views
Triple Negative Breast Cancer Key Companies
Appendix

For further information on the Triple Negative Breast Cancer pipeline therapeutics, reach out @ Triple Negative Breast Cancer Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/oral-electrolyte-solutions-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 | Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.

Chronic Kidney Disease Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, and others.

DelveInsight’s, “Chronic Kidney Disease Pipeline Insights 2023” report provides comprehensive insights about 76+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Chronic Kidney Disease Pipeline Report

DelveInsight’s Chronic Kidney Disease pipeline report depicts a robust space with 76+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
The leading companies working in the Chronic Kidney Disease market include Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies, Inc., MISSION Therapeutics, AceLink Therapeutics, and others.
Promising Chronic Kidney Disease Pipeline Therapies in the various stages of development roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.
September 2023: Prokidney announced a study of phase 3 clinical trials for Renal Autologous Cell Therapy (REACT). The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
September 2023: Bayer announced a study of phase 3 clinical trials for Finerenone (BAY94-8862). The participants will take finerenone or a placebo once a day as tablets by mouth. All of the participants will also continue to take their current medicine for their CKD. The participants will be in the trial for up to about 50 months.

Request a sample and discover the recent advances in Chronic Kidney Disease Treatment Drugs @ Chronic Kidney Disease Pipeline Report

In the Chronic Kidney Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Chronic Kidney Disease Overview

Chronic Kidney Disease is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease.

Find out more about Chronic Kidney Disease Therapeutics Assessment @ Chronic Kidney Disease Preclinical and Discovery Stage Products

Chronic Kidney Disease Emerging Drugs Profile

KBP-5074: KBP Biosciences
Ziltivekimab: Novo Nordisk
US-APR2020: Kibow Pharma
DM199: DiaMedica Therapeutics
AL-01211: AceLink Therapeutics

Chronic Kidney Disease Pipeline Therapeutics Assessment

There are approx. 76+ key companies which are developing the Chronic Kidney Disease therapies. The Chronic Kidney Disease companies which have their Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase III include, KBP Biosciences.

DelveInsight’s Chronic Kidney Disease Pipeline Report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Chronic Kidney Disease Pipeline Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn more about the emerging Chronic Kidney Disease Pipeline Therapies @ Chronic Kidney Disease Clinical Trials Assessment

Scope of the Chronic Kidney Disease Pipeline Report

Coverage- Global
Chronic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Chronic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Chronic Kidney Disease Companies- Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies, Inc., MISSION Therapeutics, AceLink Therapeutics, and others.
Chronic Kidney Disease Pipeline Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.

Dive deep into rich insights for new drugs for Chronic Kidney Disease Treatment, Visit @ Chronic Kidney Disease Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Chronic Kidney Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chronic Kidney Disease– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
KBP-5074: KBP Biosciences
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
DM199: DiaMedica Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AL-01211: AceLink Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
SCO-116: Scohia Pharma
Drug profiles in the detailed report…..
Inactive Products
Chronic Kidney Disease Key Companies
Chronic Kidney Disease Key Products
Chronic Kidney Disease- Unmet Needs
Chronic Kidney Disease- Market Drivers and Barriers
Chronic Kidney Disease- Future Perspectives and Conclusion
Chronic Kidney Disease Analyst Views
Chronic Kidney Disease Key Companies
Appendix

For further information on the Chronic Kidney Disease Pipeline therapeutics, reach out to Chronic Kidney Disease Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Kidney Disease Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, and others.

Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023 | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma

DelveInsight’s, “Psoriasis Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Psoriasis Pipeline Report

DelveInsight’s Psoriasis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Psoriasis treatment.
The leading companies working in the Psoriasis Market include Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
Promising Psoriasis Pipeline Therapies in the various stages of development include GN-037, Clobetasol 17-propionate, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, KX01 0.01% (0.1 mg/g), and others.
October 2023: Mylan Pharmaceuticals Inc. announced a study of Phase 3 clinical trials for Humira 40 MG in Prefilled Syringe. A Multicenter, Randomized, Blinded, Parallel Group, Interchangeability Study in Moderate to Severe Chronic Plaque Psoriasis Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity Between Subjects Receiving Humira® Pre Filled Syringe (40 mg) Continuously and Subjects Undergoing Repeated Switches Between Humira® Pre Filled Syringe (40 mg) and Hulio Pre-filled Syringe (40 mg).
September 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for BMS-986165. The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

Request a sample and discover the recent advances in Psoriasis Treatment Drugs @ Psoriasis Infection Pipeline Outlook Report

In the Psoriasis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Psoriasis Overview

Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors. It is a non-contagious dermatosis disease affecting almost 2% of the world population. The percentage of body affected by psoriasis can vary on an individual basis.

Find out more about Psoriasis Treatment Landscape @ Drugs for Psoriasis Treatment

Psoriasis Emerging Drugs Profile

Topical roflumilast: Arcutis Biotherapeutics
GSK2982772: GlaxoSmithKline

Psoriasis Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Psoriasis. The Psoriasis companies which have their Psoriasis drug candidates in the most advanced stage, i.e. Registered include, Biocad.

DelveInsight’s Psoriasis pipeline report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

The Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravitreal
Subretinal
Topical.
Molecule Type

Psoriasis Pipeline Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Learn more about the emerging Psoriasis Pipeline Therapies @ Psoriasis Clinical Trials Assessment

Scope of the Psoriasis Pipeline Report

Coverage- Global
Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Psoriasis Companies- Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
Psoriasis Pipeline Therapies- GN-037, Clobetasol 17-propionate, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, KX01 0.01% (0.1 mg/g), and others.

Dive deep into rich insights for new drugs for Psoriasis treatment, Visit @ Psoriasis Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Psoriasis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Psoriasis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Psoriasis Collaboration Deals
Late Stage Products (Phase III)
CT-P43: Celltrion
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
EDP1815: Evelo Biosciences
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AZD0284: AstraZeneca
Drug profiles in the detailed report…..
Early Stage Products (Preclinical)
AZD0284: AstraZeneca
Drug profiles in the detailed report…..
Inactive Products
Psoriasis Key Companies
Psoriasis Key Products
Psoriasis- Unmet Needs
Psoriasis- Market Drivers and Barriers
Psoriasis- Future Perspectives and Conclusion
Psoriasis Analyst Views
Psoriasis Key Companies
Appendix

For further information on the Psoriasis pipeline therapeutics, reach out @ Psoriasis Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023 | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma

Refractory Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda, and others.

DelveInsight’s, “Refractory Multiple Myeloma Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the Refractory Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Refractory Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Refractory Multiple Myeloma Pipeline Report

DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Refractory Multiple Myeloma treatment.
The leading companies working in the Refractory Multiple Myeloma Market include NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, and others.
Promising Refractory Multiple Myeloma Pipeline Therapies in the various stages of development include Venetoclax, Dexamethasone, Carfilzomib, Elotuzumab, Thalidomide, Cyclophosphamide, and others.
December 2023: Regeneron Pharmaceuticals announced a study of Phase 3 clinical trials for Linvoseltamab, Elotuzumab, Pomalidomide and Dexamethasone. This study is focused on participants who have multiple myeloma that has returned or needs to be treated again after one to four prior treatments and have standard cancer treatment options available to them. The aim of the study is to see how safe and effective linvoseltamab is compared to a combination of three cancer drugs: elotuzumab, pomalidomide and dexamethasone (called “EPd” in this form), one of these standard treatment options. Half of the participants in this study will get linvoseltamab, and the other half will get EPd. Both linvoseltamab and EPd will be referred to as “study drugs” in this form.
December 2023: Hoffmann-La Roche announced a study of Phase 1 clinical trials for Forimtamig, Carfilzomib, and Daratumumab. The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in participants with relapsed or refractory multiple myeloma (r/r MM). The study consists of two phases: a dose exploration phase and a dose-expansion phase.
December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Mezigdomide, Carfilzomib, and Dexamethasone. The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Request a sample and discover the recent advances in Refractory Multiple Myeloma Treatment Drugs @ Refractory Multiple Myeloma Infection Pipeline Report

In the Refractory Multiple Myeloma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Refractory Multiple Myeloma Overview

Multiple myeloma is a cancer that starts in a type of white blood cell called a plasma cell. It’s relatively rare, making up less than 2 percent, but it’s the most common type of plasma cell tumor, according to the CDC. The survival rate of multiple myeloma has improved in recent years, but initial treatment still isn’t effective at completely getting rid of the cancer in the vast majority.

Find out more about Refractory Multiple Myeloma Treatment Drugs @ Drugs for Refractory Multiple Myeloma Treatment

Refractory Multiple Myeloma Emerging Drugs Profile

NEXI 002: NexImmune
AMG-701: Amgen
ABBV 453: AbbVie

Refractory Multiple Myeloma Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Refractory Multiple Myeloma. The Refractory Multiple Myeloma companies which have their Refractory Multiple Myeloma drug candidates in the most advanced stage, i.e. Phase I/II include, NexImmune.

DelveInsight’s Refractory Multiple Myeloma pipeline report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Refractory Multiple Myeloma Pipeline Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Learn more about the emerging Refractory Multiple Myeloma Pipeline Therapies @ Refractory Multiple Myeloma Clinical Trials Assessment

Scope of the Refractory Multiple Myeloma Pipeline Report

Coverage- Global
Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Refractory Multiple Myeloma Companies- NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, and others.
Refractory Multiple Myeloma Pipeline Therapies- Venetoclax, Dexamethasone, Carfilzomib, Elotuzumab, Thalidomide, Cyclophosphamide, and others.

Dive deep into rich insights for new drugs for Refractory Multiple Myeloma treatment, Visit @ Refractory Multiple Myeloma Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Refractory Multiple Myeloma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Refractory Multiple Myeloma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name : Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase I/II)
NEXI 002: NexImmune
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ABBV 453: AbbVie
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name : Company name
Drug profiles in the detailed report…..
Inactive Products
Refractory Multiple Myeloma Key Companies
Refractory Multiple Myeloma Key Products
Refractory Multiple Myeloma- Unmet Needs
Refractory Multiple Myeloma- Market Drivers and Barriers
Refractory Multiple Myeloma- Future Perspectives and Conclusion
Refractory Multiple Myeloma Analyst Views
Refractory Multiple Myeloma Key Companies
Appendix

For further information on the Refractory Multiple Myeloma pipeline therapeutics, reach out @ Refractory Multiple Myeloma Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Refractory Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda, and others.

CAR-T Therapy Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, and other

DelveInsight’s, “CAR-T Therapy Pipeline Insight 2023” report provides comprehensive insights about 200+ companies and 252+ pipeline drugs in the CAR-T Therapy pipeline landscape. It covers the CAR-T Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the CAR-T Therapy Pipeline Report

DelveInsight’s CAR-T Therapy pipeline report depicts a robust space with 200+ active players working to develop 252+ pipeline therapies for CAR-T Therapy treatment.
The leading companies working in the CAR-T Therapy Market include CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
Promising CAR-T Therapy Pipeline Therapies in the various stages of development include Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.
December 2023: Novartis Pharmaceuticals announced a study of Phase 2 clinical trials for PHE885. A Phase 2 Study of PHE885, B-cell Maturation Antigen (BCMA)- Directed CAR-T Cells in Adult Participants With Relapsed and Refractory Multiple Myeloma.
December 2023: Allogene Therapeutics announced a study of Phase 1 clinical trials for ALLO-501, ALLO-647, Fludarabine and Cyclophosphamide. The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
November 2023: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd announced a study of Phase 1 clinical trials for CD19 CAR-T cells. This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
November 2023: Chongqing Precision Biotech Co., Ltd announced a study of Phase 1 clinical trials for CEA CAR-T cells. This trial is an open-label, single-arm clinical study. The main purpose is to verify the safety and efficacy of CAR-T cell preparations in the treatment of CEA-positive advanced malignant tumors, and to obtain the recommended dose and infusion scheme of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignant tumors.

Request a sample and discover the recent advances in CAR-T Therapy Treatment Drugs @ CAR-T Therapy Pipeline Report

In the CAR-T Therapy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR-T Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

CAR-T Therapy Overview

Chimeric Antigen Receptors (CARs), also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor.

Find out more about CAR-T Therapy Treatment Drugs @ Drugs for CAR-T Therapy Treatment

CAR-T Therapy Emerging Drugs Profile

CT053: Carsgen Therapeutics
Descartes-08: Cartesian Therapeutics
ALLO-501A: Allogene Therapeutics
CTX110: CRISPR Therapeutics
IMPT 314: ImmPACT Bio
ALLO-715: Allogene Therapeutics

CAR-T Therapy Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the therapies for CAR-T Therapy. The CAR-T Therapy companies which have their CAR-T Therapy drug candidates in the most advanced stage, i.e. Registered include, Carsgen Therapeutics.

DelveInsight’s CAR-T Therapy pipeline report covers around 252+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

CAR-T Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

CAR-T Therapy Pipeline Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn more about the emerging CAR-T Therapy Pipeline Therapies @ CAR-T Therapy Clinical Trials Assessment

Scope of the CAR-T Therapy Pipeline Report

Coverage- Global
CAR-T Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
CAR-T Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
CAR-T Therapy Companies- CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
CAR-T Therapy Pipeline Therapies- Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.

Dive deep into rich insights for new drugs for CAR-T Therapy treatment, Visit @ CAR-T Therapy Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
CAR-T Therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
CAR-T Therapy– DelveInsight’s Analytical Perspective
Late Stage Products (Registered)
CT053: Carsgen Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Descartes-08: Cartesian Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ALLO-715: Allogene Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
ACLX 003: Arcellx
Drug profiles in the detailed report…..
Inactive Products
CAR-T Therapy Key Companies
CAR-T Therapy Key Products
CAR-T Therapy- Unmet Needs
CAR-T Therapy- Market Drivers and Barriers
CAR-T Therapy- Future Perspectives and Conclusion
CAR-T Therapy Analyst Views
CAR-T Therapy Key Companies
Appendix

For further information on the CAR-T Therapy pipeline therapeutics, reach out @ CAR-T Therapy Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR-T Therapy Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, and other

Simplify Paralleling Switchgear Updates in ASCO Power Webinar

Attendees will learn the value of renewing instead of replacing paralleling switchgear to achieve significant benefits.

Florham Park, N.J., USA – December 4, 2023 – Paralleling switchgear can be upgraded to expand functionality and increase savings without disrupting operations. On December 11, 2023, power professionals can join ASCO Power Technologies Business Development Manager Dominic Magni and Regional Project Manager Aaron Samuels in a webinar titled How to Design Power Control System Modernization Projects.

The discussion will help power professionals aid their clients in executing projects more quickly at a lower cost. Hosted jointly by ASCO Power Technologies and Consulting Specifying Engineer, this webinar will be led by ASCO’s experts. Attendees can ask presenters about critical backup power topics and applications.

“Join us as we provide insight into the capabilities and benefits of Power Control System Modernization and Project Execution,” says Business Development Manager Dominic Magni. “Specifiers will learn how to streamline projects, drive savings, enhance sustainability, and maintain continuity. Attendees will gain valuable insights that help facilities thrive in this ever-evolving energy landscape.”

By attending the event, professionals will:

Learn the basics of power control system modernization.
Know when to specify a power control system upgrade or modification.
Review drawing markup packages and sequences of operation options.
Understand component-, door-, and panel-level modernization options.
Review examples and case studies.

To learn the benefits of power control system modernization, register here.

Visit the ASCO Power events page to find upcoming events and keep up with the latest in backup power. Subscribe to the ASCO Power newsletter to receive industry news and company updates in your inbox.

About ASCO Power Technologies 

ASCO Power Technologies has provided power reliability solutions for more than 125 years. As part of Schneider Electric, ASCO Power offers industry-leading power source and load management solutions that maximize resilience and sustainability to solve emerging power challenges. The firm designs, manufactures, services, and supports automatic transfer switches, power control systems, and critical power management appliances. ASCO products serve mission-critical functions in data centers, healthcare facilities, telecommunication networks, commercial buildings, and industrial operations.

Media Contact
Company Name: ASCO Power Technologies
Contact Person: Laurence Grodsky
Email: Send Email
Phone: + 1 973 307 7352
Address:160 Park Avenue
City: Florham Park
State: New Jersey
Country: United States
Website: https://www.ascopower.com/us/en/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Simplify Paralleling Switchgear Updates in ASCO Power Webinar

Glioblastoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, and others.

DelveInsight’s, “Glioblastoma Pipeline Insight 2023” report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in the Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Glioblastoma Pipeline Report

DelveInsight’s Glioblastoma pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma treatment.
The leading companies working in the Glioblastoma Market include Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
Promising Glioblastoma Pipeline Therapies in the various stages of development include Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.
November 2023: Boston Scientific Corporation announced a study of early Phase 1 clinical trials for TheraSphere GBM. The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
November 2023: Chimeric Therapeutics announced a study of Phase 1 clinical trials for CHM-1101 CAR-T cells. This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive).
November 2023: In8Bio Inc. announced a study of Phase 1 & 2 clinical trials for Autologous genetically modified gamma-delta T cells. A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma.
November 2023: Novartis Pharmaceuticals announced a study of Phase 1 clinical trials for Temozolomide and Radiotherapy. A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent.

Request a sample and discover the recent advances in Glioblastoma Treatment Drugs @ Glioblastoma Pipeline Outlook Report

In the Glioblastoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Glioblastoma Overview

Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations.

Find out more about Glioblastoma Treatment Landscape @ Drugs for Glioblastoma Treatment

Glioblastoma Emerging Drugs Profile

Enzastaurin: Denovo BioPharma
Tofacitinib: Pfizer
VT1021: Vigeo Therapeutics
Varlilumab: Celldex Therapeutics
Debio 0123: Debiopharm
PRT3645: Prelude Therapeutics

Glioblastoma Pipeline Therapeutics Assessment

There are approx. 195+ key companies which are developing the therapies for Glioblastoma. The Glioblastoma companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Denovo BioPharma.

DelveInsight’s Glioblastoma pipeline report covers around 210+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Glioblastoma Pipeline Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn more about the emerging Glioblastoma Pipeline Therapies @ Glioblastoma Clinical Trials Assessment

Scope of the Glioblastoma Pipeline Report

Coverage- Global
Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Glioblastoma Companies- Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
Glioblastoma Pipeline Therapies- Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.

Dive deep into rich insights for new drugs for Glioblastoma treatment, Visit @ Glioblastoma Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Glioblastoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Glioblastoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Enzastaurin: Denovo BioPharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Varlilumab: Celldex Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
PRT3645: Prelude Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
ELC-401: Elicera Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Glioblastoma Key Companies
Glioblastoma Key Products
Glioblastoma- Unmet Needs
Glioblastoma- Market Drivers and Barriers
Glioblastoma- Future Perspectives and Conclusion
Glioblastoma Analyst Views
Glioblastoma Key Companies
Appendix

For further information on the Glioblastoma pipeline therapeutics, reach out @ Glioblastoma Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioblastoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, and others.

NK Cell Therapy Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Synimmune, and others

DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the NK Cell Therapy Pipeline Report

DelveInsight’s NK Cell Therapy pipeline report depicts a robust space with 100+ active players working to develop 185+ pipeline therapies for NK Cell Therapy treatment.
The leading companies working in the NK Cell Therapy Market include ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.
Promising NK Cell Therapy Pipeline Therapies in the various stages of development include Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.
November 2023: Precision Biotech Taiwan Corp. announced a study of Phase 1 & 2 clinical trials for donor-derived NK cell infusion. A Phase Ι & IIa, Open-label Study to Evaluate Safety and Efficacy of the Combination Therapy of Allogeneic PB103 and Standard Cancer Treatment in the IIIB/IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Patients.
November 2023: NKGen Biotech Inc. announced a study of Phase 1 clinical trials for SNK02. A Phase 1, Open-Label, Dose Escalation Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Participants With Pathologically Confirmed Cancer Refractory to Conventional Therapy.

Request a sample and discover the recent advances in NK Cell Therapy Treatment Drugs @ NK Cell Therapy Infection Pipeline Report

In the NK Cell Therapy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Natural Killer (NK) cell therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

NK Cell Therapy Overview

Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm.

Find out more about NK Cell Therapy Treatment Landscape @ Drugs for NK Cell Therapy Treatment

NK Cell Therapy Emerging Drugs Profile

NKTR-214: Nektar therapeutics
Monalizumab: Innate Pharma
Bemarituzumab: Five Prime Therapeutics
ALT 803: ImmunityBio
CellProtect: XNK Therapeutics
K-NK002: Kiadis Pharma
NK-92: ImmunityBio
WU-NK-101: Wugen
Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
ALECSAT: CytoVac

NK Cell Therapy Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Natural Killer (NK) cell therapy. The NK Cell Therapy companies which have their Natural Killer (NK) cell therapy drug candidates in the most advanced stage, i.e. Phase III include, Nektar therapeutics.

NK Cell Therapy Segmentation:-

DelveInsight’s NK Cell Therapy pipeline report covers around 185+ products under different phases of clinical development like

Late-stage products (Phase III and
Mid-stage products (Phase II and
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

NK Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion
Intradermal
Intramuscular
Intranasal
Intravaginal
Oral
Parenteral
Subcutaneous
Topical.
Molecule Type

NK Cell Therapy Pipeline Products have been categorized under various Molecule types such as

Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule
Product Type

Learn more about the emerging NK Cell Therapy Pipeline Therapies @ NK Cell Therapy Clinical Trials Assessment

Scope of the NK Cell Therapy Pipeline Report

Coverage- Global
NK Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
NK Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
NK Cell Therapy Companies- ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.
NK Cell Therapy Pipeline Therapies- Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.

Dive deep into rich insights for new drugs for NK Cell Therapy treatment, Visit @ NK Cell Therapy Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Natural Killer (NK) cell therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
NKTR-214: Nektar therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
CellProtect: XNK Therapeutics
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
Drug profiles in the detailed report…..
Inactive Products
Natural Killer (NK) cell therapy Key Companies
Natural Killer (NK) cell therapy Key Products
Natural Killer (NK) cell therapy- Unmet Needs
Natural Killer (NK) cell therapy- Market Drivers and Barriers
Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
Natural Killer (NK) cell therapy Analyst Views
Natural Killer (NK) cell therapy Key Companies
Appendix

For further information on the NK Cell Therapy pipeline therapeutics, reach out @ NK Cell Therapy Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NK Cell Therapy Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Synimmune, and others

North America Confectionery Market Surge: USA’s $28.2 Billion Boom in 2023

“North America Confectionery Market 2024-2032”

The expansion of North America’s confectionery market is propelled by the rising demand for sugary treats like gums, jellies, chocolates, and snack bars. This trend is largely due to the diverse range of flavors, shapes, and sizes available in these products.

The latest research from Expert Market Research, titled ‘North America Confectionery Market Share, Size, Analysis and Forecast 2024-2032′, offers a comprehensive review of the confectionery market in North America. This report evaluates the market through various segments, including types of confectioneries and key regional markets within North America.

This study tracks current industry trends and their influence on the overall market. It also examines the dynamics of the market, focusing on crucial demand and price indicators. Additionally, the report provides an analysis of the market utilizing both SWOT analysis and Porter’s Five Forces models to give a detailed perspective on the market’s structure and competitive landscape.

The key highlights of the report include:

Market Overview (2018-2032)

Forecast CAGR (2024-2032): 1.9% (United States Confectionery Market)

North America Confectionery Market Share

The North America confectionery market is a dynamic and significant sector within the global confectionery industry. Characterized by a diverse range of products, including chocolates, candies, gums, and snack bars, this market enjoys a substantial share due to its large consumer base with varied preferences.

Get a Free Sample Report with Table of Contents@ https://bityl.co/MjIB

The United States, being a key player, dominates the market in terms of both production and consumption, followed closely by Canada. Market share is influenced by factors like innovative product launches, growing consumer interest in premium and artisanal confectioneries, and a steady demand for traditional sweets.

The rise in health-conscious consumers is also steering the market towards sugar-free and organic options, further diversifying the market share within this region. The integration of online retail and e-commerce platforms has expanded market reach, making confectionery products more accessible to a wider audience, thereby enhancing market penetration and share in North America.

The North American confectionery market is experiencing growth, primarily fueled by the rising popularity of sugar-rich treats such as gums, jellies, chocolates, and snack bars, among others. This trend is largely due to the wide array of available flavors, shapes, and sizes of these confectionery items.

Looking ahead, the market is expected to see further growth, spurred by an increasing demand for confectioneries during special occasions and festivals like Christmas and Easter, which typically boost confectionery sales. Additionally, the robust presence and strategic expansion efforts of leading market players in the United States are anticipated to be key drivers in propelling the market forward in the upcoming years.

Read Full Report with Table of Contents@ https://bityl.co/MjID

Defining North America’s Confectionery Sector and Key Categories

Confectionery items are snack products characterized by their high sugar and carbohydrate content. These treats are crafted to delight consumers’ taste buds, often being associated with enjoyment and indulgence. Typically consumed during special events or festive occasions, confectionery products also feature a variety of food colorings and innovative flavors, adding to their appeal.

On the basis of type, the market can be segmented into:

Chocolate

White

Milk

Dark

Non-Chocolate

Gums & Mints

The major countries in the North America confectionery market include:

United States of America

Canada

Trends in the Confectionery Market of North America

Market trends indicate significant business prospects in the United States and Canada, bolstered by government backing. This support is nurturing advancements in product innovation and research and development, focused on crafting superior confectionery items featuring unique flavors and ingredients. Additionally, the rise of vegan confectionery options, particularly those with reduced sugar and gluten-free attributes, is expected to fuel market growth shortly. Furthermore, the swift growth of the e-commerce sector in this region is set to enhance the accessibility and appeal of confectionery products to a broader audience, including new potential customers.

North America Confectionery Market Growth

The North America Confectionery Market is experiencing robust growth, driven by diverse consumer preferences and innovative product offerings. Key factors fueling this expansion include the rising popularity of premium and artisanal confectioneries, a growing inclination towards health-conscious choices like organic and sugar-free options, and the increased demand for unique and exotic flavors. The United States, as a major market contributor, continues to set trends with its wide variety of confectionery products, while Canada’s market is also showing considerable growth. Additionally, the integration of e-commerce and digital marketing strategies has broadened the reach of confectionery products, making them more accessible to a wider audience and thus contributing to the overall growth of the confectionery market in North America.

North America Confectionery Market Forecast

The forecast for the North America Confectionery Market points towards continued growth and evolution. This expansion is anticipated to be driven by several key factors, including ongoing innovation in flavors and product formats, a greater emphasis on health-conscious and ethical options like organic, sugar-free, and vegan confectioneries, and the impact of evolving consumer preferences. The United States is expected to maintain its dominance in the market, with ongoing product development and marketing strategies tailored to diverse consumer groups.

Additionally, the market is likely to see a boost from the growing influence of e-commerce and digital marketing, making confectionery products more accessible to a broader audience. The Canadian market is also projected to show significant growth, contributing to the overall expansion of the sector in North America. Furthermore, seasonal and festive sales, along with the introduction of innovative and niche products, are expected to play a crucial role in driving market dynamics during the forecast period.

Key Market Players

The major players in the market are:

The Hershey Company

Nestle S.A (Nestle USA)

Mars Inc.

Ferrero SpA

Mondelez International, Inc.

Chocoladefabriken Lindt & Sprüngli AG

The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

Read Our Top Trending Related Reports:

South Korea Honey Market: https://bityl.co/MjHi

Mexico Frozen Fruits Market: https://bityl.co/MjHj

Malaysia Cordial Drink Market: https://bityl.co/MjHk

India Online Food Delivery Market: https://bityl.co/MjHl

South Korea Vegan Chocolate Market: https://bityl.co/MjHm

About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analysis provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today’s competitive market.

Don’t miss the opportunity to elevate your business intelligence and strengthen your strategic planning. Secure your organisation’s future success by acquiring one of our Expert Market Research reports today.

Media Contact
Company Name: Expert Market Research
Contact Person: Matt Johnson
Email: Send Email
Phone: +1-415-325-5166
Address:30 North Gould Street
City: Sheridan
State: Wyoming
Country: United States
Website: https://www.expertmarketresearch.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: North America Confectionery Market Surge: USA\’s $28.2 Billion Boom in 2023

Unveiling the Future: South Korea’s Artificial Intelligence Market (2024-2032)

“South Korea artificial intelligence market 2024-2032”

The South Korea artificial intelligence market size reached a staggering USD 1,011.04 million in 2023, signaling a new era of technological advancements in the country. This dynamic market is on a trajectory to expand at a CAGR of 15.3% between 2024 and 2032, culminating in a projected value of USD 3,614.26 million by 2032. Such growth is indicative of South Korea’s commitment to integrating AI in various sectors, making it a pivotal player in the global AI landscape.

The ‘South Korea Artificial Intelligence Market Size, Share, Forecast and Analysis (2024-2032)’ by Expert Market Research offers a comprehensive review of the artificial intelligence sector in South Korea. This detailed report evaluates the market through various segments, including product and service types, technological advancements, and end-user applications.

This study provides insights into the most recent developments within the market and their wide-ranging effects. Additionally, it examines both the current demand for artificial intelligence in South Korea and key factors influencing pricing and demand. The report further explores the market dynamics using tools such as SWOT analysis and Porter’s Five Forces Model, offering a strategic perspective on the market’s growth and challenges.

The key highlights of the report include:

Market Overview (2018-2032)

Historical Market Size (2023): USD 1,011.04 Million
Forecast CAGR (2024-2032): 15.3%
Forecast Market Size (2032): USD 3,614.26 million

In the past decade, South Korea’s artificial intelligence (AI) sector has experienced a remarkable surge, marked by the filing of over 6000 AI-centric patents. Looking ahead, the AI market in South Korea is poised for further expansion, particularly in the commercialization of AI products and services. The adoption of pay-as-you-go AI solutions is gaining momentum, enabling businesses to experiment with AI features without substantial initial investments. This increasing embracement of AI technologies is anticipated to be a significant driving force for the market’s growth in the near future.

Get a Free Sample Report with Table of Contents@ https://bityl.co/MjEe

The South Korea AI market is finding fertile ground for growth across various sectors, including security, manufacturing, healthcare, and automotive. These industries present attractive prospects for the market’s expansion. Furthermore, the government’s dedicated initiatives to bolster the digital infrastructure of the country are also playing a crucial role in advancing the AI market.

In recent times, technologies like data digitalization, natural language processing, and machine learning have seen rapid advancement and proliferation. The growing need for sophisticated text analytics and the advancements in machine-to-machine technology are central to driving the growth of South Korea’s AI market.

Defining South Korea’s Artificial Intelligence Sector and Its Key Components

Artificial intelligence (AI) is a branch of computer science focused on creating systems or machines that display human-like intelligence. This involves the ability to analyze, make decisions, and learn from previous experiences. The progress in AI technology has enabled the integration of human-like cognitive functions in machines, encompassing skills like reasoning, generalizing from existing data, and deriving insights from past interactions.

Read Full Report with Table of Contents@ https://bityl.co/MjEY

On the basis of product and service, the market is segmented into:

Hardware

Software

Service

Based on technology, the market is classified into:

Machine Learning

Natural Language Processing

Others

On the basis on end use, the market is categorised into:

Security

Media and Advertising

Retail

Automotive

Healthcare

Manufacturing

Others

Trends in the South Korean Artificial Intelligence Market

In the South Korean artificial intelligence (AI) market, several key trends are shaping its future. Notably, there’s an uptick in investment and research by major companies focusing on the commercialization of AI products and services for both domestic and international markets. The burgeoning information technology sector, along with a heightened adoption of cloud-based solutions, is anticipated to further propel market growth. These solutions are critical for enhancing operational efficiency and processing large data sets.

Moreover, advancements in 5G technology and a growing demand for virtual assistants are expected to boost the need for AI in South Korea. The automotive industry is also witnessing a surge in the use of AI, particularly with the increasing popularity of self-driving vehicles, which in turn is stimulating market growth.

In the realm of media and advertising, AI is increasingly used to improve streaming services, particularly with the rising popularity of OTT platforms. This trend is likely to positively influence the growth of South Korea’s AI market. In healthcare, the escalating incidence of chronic diseases is driving the adoption of AI for remote patient monitoring and disease identification, further contributing to the sector’s expansion.

Leading Participants in the South Korean Artificial Intelligence Market

The prominent companies featured in the South Korea artificial intelligence market report include:

Samsung Electronics Co. Ltd

SK Telecom Co., Ltd.

KT Corporation

LG Corporation

Kakao Enterprise

Microsoft Corporation

Google LLC

Amazon Web Services, Inc.

Riiid, Inc.

Additional key players

The report provides an in-depth analysis of various aspects of these market participants, including their market shares, production capacities, facility turnarounds, and expansions. It also delves into their recent investments, as well as mergers and acquisitions, alongside other noteworthy developments in the market.

Read Our Top Trending Reports:

South Korea Honey Market: https://bityl.co/MjED

South Korea Hybrid Cars Market: https://bityl.co/MjEC

South Korea Luxury Goods Market: https://bityl.co/MjEB

South Korea Functional Water Market: https://bityl.co/MjEI

South Korea Health Supplements Market: https://bityl.co/MjEE

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Unveiling the Future: South Korea\’s Artificial Intelligence Market (2024-2032)